Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AF-Only Defibrillator Therapy May Be Five Years Away, Investigator Says

This article was originally published in The Gray Sheet

Executive Summary

Implantable defibrillator therapy for the nearly 4 mil. atrial fibrillation patients not requiring ventricular defibrillation is at least three to five years away, Northwestern University electrophysiologist Alan Kadish, MD, indicated at the recent Lehman Brothers Healthcare Conference in Orlando, Florida.

You may also be interested in...

Medtronic Increases Lead In Afib Market Following Gem III AT Approval

Medtronic says its Gem III AT dual-chamber implantable cardioverter defibrillator (ICD), approved by FDA via PMA supplement Feb. 13, represents a more compact and powerful alternative to the company's Jewel AF for patients also at risk of atrial tachyarrhythmias. The firm began shipments immediately.

Biosense Webster Develops First AF Ablation Catheter Following Atrionix Buy

J&J/Cordis' $62.8 mil. cash acquisition of Atrionix rounds out Biosense Webster's electrophysiology product line with a catheter-based ablation approach to atrial fibrillation (AF).

Medtronic Jewel AF-Only Indication Outcomes Study Recommended By Panel

A postmarket surveillance study of Medtronic's Jewel AF (model 7250) implantable cardioverter defibrillator for atrial fibrillation would address concerns about possible complications including death and stroke rate, FDA's Circulatory System Devices Advisory Panel recommended Dec. 5 in Gaithersburg, Maryland.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts